MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Vivani Medical

Închisă

1.01 1

Rezumat

Modificarea prețului

24h

Curent

Minim

0.98

Maxim

1.01

Indicatori cheie

By Trading Economics

Angajați

36

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+292.16% upside

Dividende

By Dow Jones

Următoarele câștiguri

9 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

61M

Deschiderea anterioară

0.01

Închiderea anterioară

1.01

Vivani Medical Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

13 iun. 2024, 15:28 UTC

Principalele dinamici ale pieței

Vivani Medical Shares Up, FDA Cleared New Drug Application to Start Diabetes Trial

Comparație

Modificare preț

Vivani Medical Așteptări

Obiectiv de preț

By TipRanks

292.16% sus

Prognoză pe 12 luni

Medie 4 USD  292.16%

Maxim 4 USD

Minim 4 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVivani Medical - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

2

Cumpărare

0

Păstrare

0

Vânzare

Date financiare

$

Despre Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.